NCT01825122View on ClinicalTrials.gov

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

PHASE2CompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions

Smoking Cessation

Interventions

DRUG

Nadolol

DRUG

Placebo

Trial Locations (4)

33144

Nuren Medical, Miami

33165

Abel Buchheim Pharmaceutical Research, Miami

63110

Washington University School of Medicine, St Louis

Unknown

Hope Research Center, Phoenix

All Listed Sponsors

lead

Invion, Inc.

INDUSTRY

NCT01825122 - Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction | Biotech Hunter | Biotech Hunter